Hi All,
I love a good spreadsheet so was going to look at the NPV's associatedwith ResAppDx so I could do some sensitivities around changed input parameters both in peak year sales and revenue projections.
In setting this up I came across the following assumptions adopted byAcuity in the financial modelling, particularly around COGS and SG&A (I hadto look up what these mean) which equate to 55% of expectedrevenues.
Over the life of the economic modelling period (to 2041) this has apretty significant impact on cashflows and hence I am assuming valuations and has been applied to all 4 ofour products.
Cheers
Information from Acuity Report
COGs and SG&A definitions from a google search:
Impacts on ResAppDx cashflows (Note that I've initially adopted a discount rate of 8% with no CPI.)
If I was toassume $10M/ annum COGS/ SG&A associated with ResAppDx instead of 55% of revenue, this has asignificant impact on cashflows and NPV.
- Forums
- ASX - By Stock
- RAP
- Estimating NPV of ResAppDx
Estimating NPV of ResAppDx
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)